JP2022524814A5 - - Google Patents

Info

Publication number
JP2022524814A5
JP2022524814A5 JP2021554699A JP2021554699A JP2022524814A5 JP 2022524814 A5 JP2022524814 A5 JP 2022524814A5 JP 2021554699 A JP2021554699 A JP 2021554699A JP 2021554699 A JP2021554699 A JP 2021554699A JP 2022524814 A5 JP2022524814 A5 JP 2022524814A5
Authority
JP
Japan
Application number
JP2021554699A
Other languages
Japanese (ja)
Other versions
JPWO2020185750A5 (https=
JP2022524814A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/021842 external-priority patent/WO2020185750A1/en
Publication of JP2022524814A publication Critical patent/JP2022524814A/ja
Publication of JPWO2020185750A5 publication Critical patent/JPWO2020185750A5/ja
Publication of JP2022524814A5 publication Critical patent/JP2022524814A5/ja
Pending legal-status Critical Current

Links

JP2021554699A 2019-03-11 2020-03-10 抗lingo-1抗体を含む医薬組成物 Pending JP2022524814A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962816668P 2019-03-11 2019-03-11
US62/816,668 2019-03-11
US201962817323P 2019-03-12 2019-03-12
US62/817,323 2019-03-12
PCT/US2020/021842 WO2020185750A1 (en) 2019-03-11 2020-03-10 Pharmaceutical compositions containing anti-lingo-1 antibodies

Publications (3)

Publication Number Publication Date
JP2022524814A JP2022524814A (ja) 2022-05-10
JPWO2020185750A5 JPWO2020185750A5 (https=) 2023-03-17
JP2022524814A5 true JP2022524814A5 (https=) 2023-03-17

Family

ID=70190131

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021554699A Pending JP2022524814A (ja) 2019-03-11 2020-03-10 抗lingo-1抗体を含む医薬組成物

Country Status (14)

Country Link
US (1) US20220144945A1 (https=)
EP (1) EP3938395A1 (https=)
JP (1) JP2022524814A (https=)
KR (1) KR20210136063A (https=)
CN (1) CN113661179A (https=)
AU (1) AU2020234943A1 (https=)
BR (1) BR112021017644A2 (https=)
CA (1) CA3133072A1 (https=)
IL (1) IL286162A (https=)
MA (1) MA55298A (https=)
MX (1) MX2021010420A (https=)
TW (1) TW202103732A (https=)
UY (1) UY38605A (https=)
WO (1) WO2020185750A1 (https=)

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
DK0678122T3 (da) 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
WO1994017828A2 (en) 1993-02-09 1994-08-18 Biogen, Inc. Treatment for insulin dependent diabetes
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
WO2004085648A2 (en) 2003-03-19 2004-10-07 Biogen Idec Ma Inc. Nogo receptor binding protein
PT1776136E (pt) 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
WO2010062896A1 (en) * 2008-11-28 2010-06-03 Abbott Laboratories Stable antibody compositions and methods for stabilizing same
JP7149257B2 (ja) * 2016-07-13 2022-10-06 バイオジェン・エムエイ・インコーポレイテッド Lingo-1アンタゴニストの投与計画及び脱髄障害の処置のための使用
AU2018263868A1 (en) * 2017-05-02 2019-12-12 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
IL272773B2 (en) * 2017-08-22 2024-06-01 Biogen Ma Inc Pharmaceutical preparations containing anti-amyloid cell antibodies

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
CL2026000307A1 (es) Conjugado de anticuerpo bispecífico-fármaco de camptotecina y uso farmacéutico de este.
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)
BR102021016176A2 (https=)
BR102021016200A2 (https=)